Why JAK3 selectivity matters: biology, approved JAK inhibitors, and medicinal chemistry perspectives.

Janus kinase 3 (JAK3) has long been pursued as a potentially safer and more selective therapeutic target because of its predominant expression in hematopoietic cells, its association with common γ-chain cytokine receptors, and the presence of the non-conserved Cys909 residue near the ATP-binding site. This review examines the biological role of JAK3 in hematological malignancies and the medicinal chemistry strategies developed to achieve selective JAK3 inhibition. Particular attention is given to the evolution of covalent and non-covalent inhibitors, structural determinants of selectivity, and the translational challenges associated with JAK3-targeted drug discovery. Collectively, the available evidence suggests that biochemical selectivity alone is insufficient to predict therapeutic benefit, since γc cytokine signaling depends on cooperative JAK1/JAK3 activity. Covalent targeting of Cys909 has provided the most successful route to high intra-JAK selectivity and sustained target engagement, whereas non-covalent inhibitors continue to face challenges arising from ATP-site conservation. Current evidence further indicates that the therapeutic potential of JAK3 inhibition is most compelling in molecularly defined hematological malignancies with demonstrable JAK3 pathway dependence. Overall, the available literature supports the view that the clinical relevance of JAK3 inhibition depends not only on kinase selectivity but also on biological context, functional pathway dependence, and disease-specific molecular characteristics.